Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 4 , Pages 387-393 , December 2009

Magnetic fluid hyperthermia therapy for malignant brain tumors—an ethical discussion

Received 1 August 2008 ,Accepted 17 January 2009.

References 

  1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479–489
  2. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81:53–60
  3. Jordan A, Scholz R, Maier-Hauff K, Van Landeghem FKH, Waldoefner N, Teichgraeber U, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol. 2005;78:7–14
  4. American Brain Tumor Association (ABTA) . A primer of brain tumors. Massachusetts General Hospital Neurological Service. Available from: http://neurosurgery.mgh.harvard.edu/abta/primer.htm2005;
  5. Merkel R, Boer G, Fegert J, Galert T. Intervening in the brain. Changing psyche and society. Berlin, Heidelberg: Springer Verlag; 2007;
  6. Müller S. Minimal-invasive und nanoskalige Therapien von Gehirnerkrankungen—Eine medizinethische Diskussion. In:  Nordmann A,  Schummer J,  Schwarz A editor. Nanotechnologien im Kontext. Berlin: Akademische Verlagsgesellschaft; 2006;p. 345–370
  7. Müller S. Dilemmata bei operativen Eingriffen in das Gehirn. In:  Groß D,  Müller S editor. Sind die Gedanken frei?. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft; 2007;p. 229–268
  8. Loh A, Simon D, Kriston L, Härter M. Shared decision-making in medicine [review]. Dtsch Ärztebl. 2007;104:A1483–A1488
  9. Scheibler F. Shared decision making. Bern: Verlag Hans Huber; 2004;
  10. Beauchamp TL, Childress JF. Principles of biomedical ethics. 5th ed.. Oxford: Oxford University Press; 2001;
  11. Jordan A. Size matters. How the tiny world of nanotechnology is having a big impact on the pharma industry. Next Generation Pharma. 2007;Available from: http://www.ngpharma.com/article/Issue-4/Drug-Discovery-AND-Development/Size-matters/
  12. cc-NanoChem e. V . First cancer patients successfully treated using nanotherapy. Available from: http://obsolet.cc-nanochem.de/1-media.php2004;
  13. SmallTimes . Nanoparticles fight cancer cells with lethally high ‘fever’. Available from: http://www.smalltimes.com/articles/stm_print_screen.cfm?article_id=2689672009;
  14. Gneveckow U, Jordan A, Scholz R, Brüß V, Waldöfner N, Ricke J, et al. Description and characterization of the novel hyperthermia- and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med Phys. 2004;31:1444–1451
  15. Jordan A, Scholz R, Maier-Hauff K, Johannsen M, Wust P, Nadobny J, et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumours with magnetic fluid hyperthermia. J Magn Magn Mater. 2001;225:118–126
  16. Jordan A. Thermotherapy using magnetic nanoparticles: principles and clinical application of nanotherapy. EuroNanoForum Proc. 2005;76–80
  17. Wust P, Gneveckow U, Johannsen M, Böhmer D, Henkel T, Kahmann F, et al. Magnetic nanoparticles for interstitial thermotherapy—feasibility, tolerance and achieved temperatures. Int J Hyperthermia. 2006;22:673–685
  18. Jordan A, Scholz R, Wust P, Fähling H, Felix R. Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater. 1999;201:413–419
  19. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia. 1993;9:51–68
  20. Jordan A, Wust P, Scholz R, Tesche B, Fähling H, Mitrovics T, et al. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia. 1996;12:705–722
  21. Jordan A, Scholz R, Wust P, Fähling H, Krause J, Wlodarczyk W, et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia. 1997;13:587–605
  22. Johannsen M, Thiesen B, Gneveckow U, Taymoorian K, Waldöfner N, Scholz R, et al. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic Dunning rat model of prostate cancer. Prostate. 2006;66:97–104
  23. ETC Group [homepage on the Internet]. Available from: http://www.etcgroup.org/en
  24. ETC Group. Nanotech Rx. Medical applications of nano-scale technologies: what impact on marginalized communities?. Available from: http://www.etcgroup.org/en/materials/publications.html?pub_id=5932006;
  25. Center for Responsible Nanotechnology [homepage on the Internet]. Available from: http://www.crnano.org
  26. AAP . Call for moratorium on nanotechnology. Available from: http://news.ninemsn.com.au/article.aspx?id=2552072007;
  27. Arnall AH. Future technologies, today's choices. A report for the Greenpeace Environmental Trust. London; 2003;Available from: http://www.greenpeace.org.uk
  28. Nordmann A. If and then: a critique of speculative nanoethics. Nanoethics. 2007;1:31–46
  29. Resnik DB, Tinkle SS. Ethics in nanomedicine. Nanomedicine. 2007;2:345–350
  30. Grunwald A. Nanotechnology—a new field of ethical inquiry?. Sci Eng Ethics. 2005;11:187–201
  31. Ebbesen M, Andersen S, Besenbacher F. Ethics in nanotechnology: starting from scratch?. Bull Sci Technol Soc. 2006;26:451–462
  32. Sharma HS. Nanoneuroscience: emerging concepts on nanoneurotoxicity and nanoneuroprotection. Nanomedicine. 2007;2:753–758
  33. Unfried K, Albrecht C, Klotz LO, Mikecz Av, Grether-Beck S, Schins RPF. Cellular responses to nanoparticles: target structures and mechanisms. Nanotoxicology. 2007;1-20:
  34. Swiss Reinsurance Company . Nanotechnologie. Kleine Teile—grosse Zukunft. Zürich, Switzerland; 2004;Available from: http://www.swissre.com/resources/48c84780455c7a06b0d0ba80a45d76a0-Publ04_Nanotech_de.pdf
  35. Kurschat R. Flüssigkeiten mit magnetischen Eigenschaften. Anwendung von Ferrofluiden in Technik und Medizin. Zurich, Switzerland Neue Zürcher Zeitung; 2005;
  36. Linkov I, Satterstrom FK, Corey LM. Nanotoxicology and nanomedicine: making hard decisions. Nanomedicine. 2008;4:167–171
  37. Lee SB. Focus on nanoparticles for cancer diagnosis and therapeutics. Nanomedicine. 2007;2:647–648
  38. Shrader-Frechette K. Nanotoxicology and ethical considerations for informed consent. Nanoethics. 2007;1:47–56
  39. Mnyusiwalla A, Daar AS, Singer PA. “Mind the gap”: science and ethics in nanotechnology. Nanotechnology. 2003;14:R9–R13

 No conflict of interest was reported by the author of this paper.

PII: S1549-9634(09)00049-5

doi: 10.1016/j.nano.2009.01.011

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 4 , Pages 387-393 , December 2009

Article Tools